On March 12, 2026, investors weighed profit-taking against a high-stakes pivot toward branded obesity drugs and telehealth ...

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

Hims & Hers Health (NYSE:HIMS) looked like a fallen growth star earlier this year. The telehealth platform was hammered by the FDA’s aggressive crackdown on compounded GLP-1 drugs, complete with ...

The crucial question is whether the terms of the partnership allow for profitable expansion or merely position HIMS as a ...

Hims & Hers stock traded more than 40% higher after the deal was announced.

Hims & Hers received a flurry of upgrades, though most analysts are opting to stay on the sidelines. Here’s why.

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a ...

HIMS stock soars on a settlement and partnership with Novo Nordisk. But Hims & Hers shares are unlikely to sustain these ...

Hims & Hers Health, Inc.'s revenue is projected to reach $2.7B in 2026 & $3.2B in 2027, implying less than 2x forward sales. Read more on HIMS stock here.

In a dramatic reversal of fortune, Hims & Hers Health (NYSE:HIMS) has been rescued by the very company that nearly sank it.

Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.

Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce ...